Also known as: Maviret, MAVIRET, Mavyret, MAVYRET
Mavyret (glecaprevir/pibrentasvir) is an oral fixed-dose direct-acting antiviral combination for acute or chronic hepatitis C virus infection across genotypes 1-6 in adults and pediatric patients aged 3 years and older with appropriate liver status. It is typically given once daily with food for regimen-specific durations. Initial U.S. approval was in 2017.
Enanta Pharmaceuticals will present Phase 2b data showing zelicapavir improves RSV symptom resolution by about a week and reduces hospitalization rates. The oral N-protein inhibitor also demonstrates high resistance barrier in pediatric studies. Presentations will occur at the ESCMID Global 2026 conference in Munich.
AbbVie projects 43-45% earnings growth in 2026 as newer immunology drugs Skyrizi and Rinvoq offset declining Humira sales, while maintaining its 54-year dividend increase streak as a Dividend King.
